OBJECTIVES: The aim of the study was to analyze of use of anti-infective drugs for systemic administration (ATC-group J) in Serbia in 2011 year. METHODS: Data about use of anti-infective drugs for systemic administration in Serbia in 2011 was taken from the Agency for Drugs and Medical Devices of Serbia. RESULTS: Use of all drugs in Serbia in 2011 was 1,104.57 DDD/1000 inhabitants/day. ATC-group J was on the seventh place according to amount of DDDs with 27.35 DDD/1000 inh/day or 2.48% of total consumption. According to the funding spent, this group was on the second position with 77,800,748.63€. In this group, subgroup with highest consumption were antibacterial drugs for systemic use (subgroup J01), with 26.68 DDD/1000 inh/day or 97.55% of total use in group J. This subgroup takes first place in funding spent with 52,801,780.13€ or 67.87% of total expended finances in this group in 2011. Beta-lactam antibacterial drugs with 14.98 DDD/1000 inh/day or 56.15% were drugs with highest use in this subgroup, macrolides and lincosamides were at second place with 5.11 DDD/1000 inh/day or 19.15%, while on the third place were quinolones with 2.66 DDD/1000 inh/day or 9.97% of total drug utilization inside this subgroup. Funding spent on beta-lactam antibacterial drugs was 29,522,197.18€ or 55.91%, macrolides and lincosamides 10,811,308.09€ or 20.48%, and for quinolones 6,286,373.19€ or 11.91% of total funding spent for subgroup J01 in 2011 year. CONCLUSIONS: In comparison to 2010 spending of group J in Serbia in 2011 year was increased for 7.72 DDD/1000 inh/day or 39.33%. However the amount of funding spent in this group of drugs was decreased for 12,850,895.28€ or 14.18%. This research was supported by Provincial Secretariat for Science and Technological Development, Autonomous Province of Vojvodina project No 114-451-2458/2011 and by Ministry of Science and Technological Development, Republic of Serbia project No 41012.